Latest On Daiichi Sankyo Company, Limited (DSKYF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-02 04:17 EST | News | AstraZeneca, Daiichi Sankyo's Enhertu shows promise in multiple cancer types in trial | N/A |  |
| 2023-05-02 04:17 EST | News | Esperion Therapeutics falls 55% in dustup with Daiichi Sankyo over milestone payments | N/A | |
| 2023-05-02 04:17 EST | News | Zymeworks and Daiichi Sankyo end bispecific antibody deal | N/A | |
| 2023-05-02 04:16 EST | News | Daiichi Sankyo, Confo ink deal to develop CNS treatments | N/A | |
| 2023-05-02 04:14 EST | News | Daiichi Sankyo Company, Limited (DSKYF) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-04-27 12:31 EST | News | Daiichi Sankyo Co. GAAP EPS of ¥56.91, revenue of ¥1.28T | N/A | |
| 2023-04-21 14:53 EST | News | Daiichi Sankyo leukemia candidate review extended three months by FDA | N/A | |
| 2023-01-31 22:27 EST | News | Daiichi Sankyo GAAP EPS of ¥45.19, revenue of ¥948.28B | N/A | |
| 2022-10-31 10:12 EST | News | Daiichi Sankyo Co. GAAP EPS of ¥30.39, revenue of ¥607.79B | N/A | |
| 2022-07-29 21:14 EST | News | Daiichi Sankyo Co. GAAP EPS of ¥730.50, revenue of ¥280.32B | N/A | |
| 2022-04-27 14:44 EST | News | Daiichi Sankyo Co. GAAP EPS of ¥34.91, revenue of ¥1.04B | N/A | |
| 2022-04-09 00:05 EST | News | Seagen stock pares earlier gains after winning patent trial in Texas (update) | N/A | |
| 2022-01-31 10:06 EST | News | Daiichi Sankyo Co. Non-GAAP EPS of ¥49.16, revenue of ¥810.96B | N/A | |
| 2021-12-28 18:27 EST | News | EMA validates AstraZeneca/Daiichi's trastuzumab deruxtecan variation application in breast cancer | N/A | |
| 2021-12-24 00:18 EST | News | AstraZeneca/Daiichi initiates late-stage Enhertu trial in lung cancer | N/A | |
| 2021-12-10 06:06 EST | News | AstraZeneca analysis on Enhertu bolsters efficacy in breast cancer | N/A | |
| 2021-10-04 17:28 EST | News | Astrazeneca/Daiichi's Enhertu nabs Breakthrough Therapy tag in U.S. for breast cancer | N/A | |
| 2021-09-22 13:13 EST | News | AstraZeneca/Daiichi's Enhertu shows promising action in late-stage breast cancer study | N/A | |
| 2021-07-31 00:40 EST | News | Daiichi Sankyo Co. reports Q1 results | N/A | |
| 2021-07-22 11:28 EST | News | Could Bristol's up to $3B Eisai deal follow in footsteps of 2019 AstraZeneca deal with Daiichi? | N/A | |
| 2021-07-22 11:28 EST | News | Bristol's up to $3B deal with Eisai puts antibody drug conjugates in the spotlight | N/A | |
| 2021-04-28 04:49 EST | News | LogicBio announces agreements with CANbridge Pharma and Daiichi Sankyo | N/A | |
| 2021-04-28 04:49 EST | News | Guardant Health teams up with Daiichi Sankyo for Guardant360 CDx in lung cancer | N/A | |
| 2021-04-27 07:19 EST | News | Esperion extends partnership with Daiichi Sankyo; receives $50M funding from Oberland Capital | N/A | |
| 2021-04-27 07:18 EST | News | Daiichi Sankyo reports FY 2020 results | N/A | |
| 2021-04-20 15:04 EST | News | AstraZeneca's Enhertu now available in U.K. for breast cancer | N/A | |
| 2021-03-30 06:02 EST | Dividend | A dividend of $13.5 has been announced on Apr 27, 2020. It will be paid Nov 30, -0001 with an ex-dividend date of Mar 30, 2021. | Neutral | |
| 2021-02-21 03:29 EST | News | Takeda and Daiichi Sankyo to begin COVID-19 vaccine trials in Japan | N/A | |
| 2021-02-01 08:53 EST | Earnings Estimate | An EPS average of $0.10 is estimated for the quarter ending on June 30, 2021. | Sell | |
| 2021-01-31 08:56 EST | Financials | Company financials have been released. | Neutral | |
| 2021-01-29 09:47 EST | News | Daiichi Sankyo reports Q3 results | N/A | |
| 2021-01-20 10:38 EST | News | EU OK's AstraZeneca, Daiichi Sankyo's Enhertu for breast cancer | N/A | |
| 2021-01-15 18:24 EST | News | AstraZeneca's antibody drug conjugate Enhertu wins expanded approval from the FDA | N/A | |
| 2020-12-10 21:45 EST | News | AZN/Daiichi Sankyo' Enhertu scores ‘impressive’ new data in HER2 breast cancer study | N/A | |
| 2020-11-26 22:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-08 01:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 17:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-02 09:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-01 07:35 EST | News | AstraZeneca/Daiichi antibody-drug conjugate nabs accelerated review in U.S. for certain type of stomach cancer | N/A | |
| 2020-11-01 07:31 EST | News | Daiichi Sankyo Co. reports 1H results | N/A | |
| 2020-09-26 14:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 06:53 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-03 06:53 EST | News | Daiichi inks milademetan license deal with Rain Therapeutics | N/A | |
| 2020-08-21 08:49 EST | News | Immunic launches early-stage study of IMU-856 in gastrointestinal disorders | N/A | |
| 2020-08-14 10:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-07 06:42 EST | News | Daiichi teams up with AstraZeneca in lung cancer study | N/A | |
| 2020-08-06 10:10 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-04 01:56 EST | News | RedHill Bio inks new agreement with Daiichi Sankyo for Movantik | N/A | |
| 2020-08-03 06:07 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-03 06:07 EST | Earnings Estimate | An EPS average of $0.62 is estimated for the quarter ending on December 31, 2020. | Buy | |
About Daiichi Sankyo Company, Limited (DSKYF):
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. The company was founded in 1899 and is headquartered in Tokyo, Japan.
General
- Name Daiichi Sankyo Company, Limited
- Symbol DSKYF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-General
- Full Time Employees 15,348
- Last Split Factor3:1
- Last Split Date2020-09-29
- Fiscal Year EndMarch
- Web URLhttp://www.daiichisankyo.com
Valuation
- Trailing PE 32.41
- Forward PE 111.11
- Price/Sales (Trailing 12 Mt.) 6.81
- Price/Book (Most Recent Quarter) 5.02
- Enterprise Value Revenue 0.05
- Enterprise Value EBITDA 0.37
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $0.27
- Next Year EPS Estimate $0.37
- Next Quarter EPS Estimate -$0.10
- Profit Margin 7%
- Return on Assets 2%
- Return on Equity 5%
- Earnings Per Share $0.97
- Revenue Per Share $0
- Gross Profit 638.59 billion
- Quarterly Earnings Growth -6.8%
ESG Rating
Highlights
- Market Capitalization 59.67 billion
- PEG Ratio 31575.3
- Analyst Target Price $13
- Book Value Per Share $17.50
Share Statistics
- Shares Outstanding 1.92 billion
- Shares Float 1.93 billion
- % Held by Insiders 102%
- % Held by Institutions 45.07%
Technicals
- Beta 0.92
- 52 Week High $36.78
- 52 Week Low $21.26
- 50 Day Moving Average 30.74
- 200 Day Moving Average 31.43
Dividends
- Forward Annual Dividend Yield 0.47%
- Payout Ratio 76%
- Dividend Date 2011-12-01
- ExDividend Date 2018-03-28
- Dividend Per Share $0.64
- Dividend Yield 0%
Daiichi Sankyo Company, Limited (DSKYF) Dividend Calendar:
DSKYF's last dividend payment was made to shareholders on December 1, 2011.
Daiichi Sankyo Company, Limited pays out 76% of its earnings out as a dividend.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Daiichi Sankyo Company, Limited (DSKYF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2020-12-31 | $N/A | $0.11 | $0.14 | -21.43% |
| 2020-09-30 | 2020-12-31 | $N/A | $0.12 | $4.33 | -97.22% |
| 2020-06-30 | 2020-09-30 | $N/A | $0.10 | $15.27 | -99.37% |
| 2020-03-31 | 2020-06-30 | $N/A | $0.15 | -$20.31 | 100.75% |
| 2019-12-31 | 2020-03-31 | $2.55 billion | -$0.02 | ||
| 2019-09-30 | 2019-12-31 | $2.13 billion | $0.33 | ||
| 2019-06-30 | 2019-09-30 | $2.3 billion | $0.10 | $9.30 | -98.92% |
| 2019-03-31 | 2019-06-30 | $2.04 billion | $0.21 | ||
| 2018-12-31 | 2019-03-31 | $2.34 billion | $0.07 | ||
| 2018-09-30 | 2018-12-31 | $1.94 billion | $0.16 | ||
| 2018-06-30 | 2018-09-30 | $2.04 billion | $0.09 | ||
| 2018-03-31 | 2018-06-30 | $2.07 billion | $0.11 | -$11.30 | 100.98% |
| 2017-12-31 | 2018-03-31 | $2.41 billion | -$0.06 | $29.00 | -100.2% |
| 2017-09-30 | 2017-12-31 | $2.04 billion | $0.17 | $24.30 | -99.3% |
| 2017-06-30 | 2017-09-30 | $2.13 billion | $0.02 | $38.50 | -99.94% |
| 2017-03-31 | 2017-06-30 | $220.72 billion | $0.13 | -$12.50 | 101.04% |
| 2016-12-31 | 2017-03-31 | $276.39 billion | -$0.16 | $19.10 | -100.82% |
| 2016-09-30 | 2016-12-31 | $0.17 | $24.00 | -99.3% | |
| 2016-06-30 | 2016-09-30 | $0.09 | $27.50 | -99.68% | |
| 2016-03-31 | 2016-06-30 | $0.15 | -$35.80 | 100.41% | |
| 2015-12-31 | 2016-03-31 | -$0.12 | $10.20 | -101.21% | |
| 2015-09-30 | 2015-12-31 | $0.16 | |||
| 2015-06-30 | 2015-09-30 | $0.14 | $28.30 | -99.49% | |
| 2015-03-31 | 2015-06-30 | $0.14 | $0.00 | ||
| 2014-12-31 | 2015-03-31 | -$0.09 | $10.40 | -100.85% | |
| 2014-09-30 | 2014-12-31 | $0.20 | $11.80 | -98.27% | |
| 2014-06-30 | 2014-09-30 | $0.13 | |||
| 2014-03-31 | 2014-06-30 | $0.09 | $8.50 | -98.9% | |
| 2013-12-31 | 2014-03-31 | -$0.06 | $0.29 | -122.14% | |
| 2013-09-30 | 2013-12-31 | $0.20 | |||
| 2013-06-30 | 2013-09-30 | $0.10 | |||
| 2013-03-31 | 2013-06-30 | $0.05 | |||
| 2012-12-31 | 2013-03-31 | $0.08 | |||
| 2012-09-30 | 2012-12-31 | $0.15 | |||
| 2012-06-30 | 2012-09-30 | $0.02 | |||
| 2012-03-31 | 2012-06-30 | $0.12 | |||
| 2011-12-31 | 2012-03-31 | -$0.04 | |||
| 2011-09-30 | 2011-12-31 | -$0.12 | |||
| 2011-06-30 | 2011-09-30 | $0.07 | |||
| 2011-03-31 | 2011-06-30 | $0.15 | |||
| 2010-12-31 | 2011-03-31 | -$0.05 | |||
| 2010-09-30 | 2010-12-31 | $0.16 | |||
| 2010-06-30 | 2010-06-30 | $0.17 |
Daiichi Sankyo Company, Limited (DSKYF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | N/A | 470.31 million |
| Income Before Tax | N/A | N/A | N/A | N/A | 671.47 million |
| Selling General Administrative | N/A | N/A | N/A | N/A | 716.02 million |
| Gross Profit | N/A | N/A | N/A | N/A | 1.83 billion |
| Ebit | N/A | N/A | N/A | N/A | 639.07 million |
| Operating Income | N/A | N/A | N/A | N/A | 639.07 million |
| Income Tax Expense | 8.5 billion | 7.7 billion | 9.56 billion | -13.58 billion | 28.68 million |
| Total Revenue | N/A | N/A | N/A | N/A | 2.55 billion |
| Cost of Revenue | N/A | N/A | N/A | N/A | 728.88 million |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | 32.4 million |
| Net Income From Continuing Operations | N/A | N/A | N/A | N/A | 642.79 million |
| Net Income Applicable to Common Shares | 24.14 billion | 25.83 billion | 31.86 billion | -5.21 billion | 643.08 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | -71.56 million | 253.76 million |
| Change to Liabilities | -10.98 billion | -30.3 billion | 40.82 billion | -244.38 million | -324.37 million |
| Total Cash Flow from Investing Activities | -6.78 billion | -70.85 billion | 48.29 billion | 111.05 million | 145.61 million |
| Net Borrowings | -20.1 billion | -97 million | -97 million | -883774.45 | -897483.35 |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | -231.51 million | -23.85 million |
| Change to Operating Activities | 7.23 billion | -7.12 billion | -19.08 billion | -74.38 million | -19.69 million |
| Change in Cash | N/A | N/A | N/A | 265.33 million | 339.37 million |
| Total Cash from Operating Activities | 55.9 billion | 55.88 billion | 55.8 billion | 354.59 million | 228.61 million |
| Depreciation | N/A | N/A | N/A | 118.02 million | 124.32 million |
| Other Cash Flow from Investing Activities | -295 million | -571 million | -167 million | 487917.15 | -1.43 million |
| Change to Inventory | N/A | N/A | N/A | 62.78 million | 7.12 million |
| Change to Account Receivables | N/A | N/A | N/A | -65.27 million | 123.95 million |
| Other Cash Flow from Financing Activities | -3.18 billion | -3.17 billion | -2.49 billion | -21.28 million | -22.68 million |
| Change to Net Income | -3.2 billion | -16.73 billion | -11.86 billion | -85.28 million | 39.95 million |
| Capital Expenditures | N/A | N/A | N/A | 57.34 million | 96.5 million |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | N/A | 6.99 billion |
| Total Stockholder Equity | N/A | N/A | N/A | N/A | 12.24 billion |
| Other Current Liabilities | 51.44 billion | 43.89 billion | N/A | N/A | 536.1 million |
| Total Assets | N/A | N/A | N/A | N/A | 19.24 billion |
| Common Stock | 50 billion | 50 billion | 50 billion | 50 billion | 460.3 million |
| Other Current Assets | 10.98 billion | 10.17 billion | N/A | N/A | 127.14 million |
| Retained Earnings | 1.27 trillion | 1.27 trillion | 1.25 trillion | 1.24 trillion | 11.51 billion |
| Other Liabilities | 283.05 billion | 285.78 billion | 258.71 billion | 264.46 billion | 2.33 billion |
| Other Assets | 136.73 billion | 135.48 billion | 116.85 billion | 126.83 billion | 1.02 billion |
| Cash | N/A | N/A | N/A | N/A | 3 billion |
| Total Current Liabilities | 313.3 billion | 296.64 billion | N/A | N/A | 2.97 billion |
| Other Stockholder Equity | 79.21 billion | 79.43 billion | 82.14 billion | 82.1 billion | 901.19 million |
| Property, Plant & Equipment | 252.35 billion | 246.81 billion | 247.87 billion | 247.05 billion | 2.23 billion |
| Total Current Assets | 1.28 trillion | 1.33 trillion | N/A | N/A | 12.81 billion |
| Long Term Investments | N/A | N/A | N/A | N/A | 945.19 million |
| Net Tangible Assets | 1.05 trillion | 1.08 trillion | 1.06 trillion | 1.06 trillion | 10.02 billion |
| Short Term Investments | N/A | N/A | N/A | N/A | 4.85 billion |
| Long Term Debt | N/A | N/A | N/A | N/A | 1.69 billion |
| Inventory | 183.9 billion | 183.26 billion | N/A | N/A | 1.59 billion |
| Accounts Payable | 241.47 billion | 232.36 billion | N/A | N/A | 2.06 billion |
Daiichi Sankyo Company, Limited (DSKYF) Chart:
Daiichi Sankyo Company, Limited (DSKYF) News:
Below you will find a list of latest news for Daiichi Sankyo Company, Limited (DSKYF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Daiichi Sankyo Company, Limited (DSKYF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Daiichi Sankyo Company, Limited (DSKYF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|